Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
Portfolio Pulse from
Acoramidis has shown sustained benefits in cardiovascular outcomes, including a significant reduction in all-cause mortality (ACM) within 36 months, according to the ATTRibute-CM study's open-label extension data.
November 18, 2024 | 4:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eidos Therapeutics' drug Acoramidis has demonstrated a 36% reduction in all-cause mortality in cardiovascular outcomes within 36 months, according to the ATTRibute-CM study.
The positive results from the ATTRibute-CM study's open-label extension data suggest that Acoramidis is effective in reducing cardiovascular risks, which is likely to boost investor confidence and positively impact Eidos Therapeutics' stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100